In 2017, the Company completed two spin-off transactions through stock dividends to shareholders. The Company remains one of the largest shareholders in each of the companies.
GCANRx is a publicly traded biopharmaceutical company, under the symbol GCAN, led by an experienced team of executives and scientists, and is focused on the the development and commercialization of cannabinoid delivery systems.
GCANRx has leveraged its licensed, patented technology platform, which has been successfully applied for drug delivery in other fields of use, for cannabis patients and consumers. GCANRx's conveyance platform can be utilized to deliver cannabis actives without requiring smoking, vaporizing, or other forms of administration. The technology is versatile in that for the first-time patients can receive personalized dosing, higher bioavailability, and a controlled rapid and/or slow release using just one, unobtrusive eluting oral patch. GCANRx's mission is to bring this technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers.
GCANRx has the exclusive worldwide license for PharMedica’s Eluting Transmucosal Patch Platform (ETP) for non-invasive drug delivery in the Cannabis field.
The company holds the rights to new delivery technologies using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides for a needle free, intra-oral systemic drug delivery. The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration.
More information can be found at www.gcanrx.com.
On September 1, 2017, the Company acquired AMDAQ Ltd, a corporation formed under the Registrar of Companies for England and Wales, in order to diversify its business model to enter into the rapidly expanding sectors of blockchain technology.
AMDAQ’s multi-faceted business model will allow the company to take advantage of the significant emerging opportunities being developed utilizing blockchain technology. The opportunities we have identified to date cross many industries, which will help minimize our exposure to any single sector. We have associated ourselves with leading experts in the field of blockchain technologies, allowing for a broad overview of exciting applications being developed, which include direct investments in blockchain applications, the AMDAQ marketplace and our TIKR division.
The AMDAQ marketplace will provide the infrastructure for the administration of pre-existing and potential ownership of both tangible and intangible assets and its adaptable structural utility can be used in parallel to any equity fundraising mechanism.
AMDAQ will allow both the documented ownership and transfer of assets for which there is no established registration process and the sub-division of ownership interests in otherwise registered assets where transfer processes may be expensive/cumbersome and/or trigger taxes and other expenses.
Using the AMDAQ platform, assets can be titled in a Smart Contract with ownership interests evidenced by ownership of an associated Ethereum token. The Smart Contract will provide not only the rules as to transfer of ownership but also automated voting mechanisms for each specific situation that requires governance decisions.
On March 8, 2019, AMDAQ Corp acquired all issued and outstanding membership units of Arch Exchange and Transfer, LLC (“ARCH”). ARCH’s business plan is to become the first transfer agent registered with the Securities and Exchange Commission dedicated to its operations strictly through blockchain technology.
More information can be found at www.amdaq.corp.